Corcept Therapeutics (CORT) Nyanmɛn Kpɛn
Corcept Therapeutics
AI bɛ́nɛ́nɛ́: CORT
AI bɛ sɔhɛn sɛn na ɛbɛ yɛ a ɛwɔ nna a ɛdi akyi, nnwɔtwe no awieeɛ ne bosome no awieeɛ. Nsakraeɛ no yɛ nea wɔhwɛ firi sika a ɛwɔ hɔ seesei. Eyinom yɛ nkyɛmu nhyehyɛeɛ, ɛnyɛ nkyɛmu a wɔde bɛyɛ adwuma.
Prix su les 6 mois derniers
Premium ɛn nyɛ AI sika tɔnɔw 1 da, 1 kɛsɛli kɛn 1 bɛn fɔlɔ ni sika tɔnɔw a ni ahunye bɛɛ.
Yɛ́lɛ́ Premium🔒 Nzɛnkan nyinmɛn
Kpɛnɛn nyanmiɛn su lɛlɛ su — kpɛnɛn nyanmiɛn su lɛlɛ kun'n su, su'n su kpɛnɛn su lɛlɛ kun'n su — yɛ Premium su.
Yɛ́lɛ́ PremiumNyanmiɛn nɛnɛn
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the development of drugs for the treatment of serious metabolic and psychiatric disorders. The company’s main product modifies the action of cortisol, also known as the “stress hormone,” by blocking cortisol’s binding to one of two known receptors—the type 2 glucocorticoid receptor.
